Volume 15, Issue 8, Pages (July 2014)

Slides:



Advertisements
Similar presentations
Volume 14, Issue 4, Pages (April 2013)
Advertisements

Volume 12, Issue 9, Pages (September 2011)
Volume 389, Issue 10072, Pages (March 2017)
Volume 357, Issue 9273, Pages (June 2001)
Volume 16, Issue 2, Pages (February 2015)
Volume 18, Issue 10, Pages (October 2017)
Volume 18, Issue 6, Pages (June 2017)
Volume 376, Issue 9747, Pages (October 2010)
Volume 18, Issue 7, Pages (July 2017)
Volume 16, Issue 9, Pages (September 2015)
Volume 15, Issue 6, Pages (May 2014)
Volume 14, Issue 4, Pages (April 2013)
Volume 377, Issue 9783, Pages (June 2011)
Volume 373, Issue 9666, Pages (March 2009)
Volume 16, Issue 13, Pages (October 2015)
Evaluation of early administration of simvastatin in the prevention and treatment of delirium in critically ill patients undergoing mechanical ventilation.
Volume 371, Issue 9611, Pages (February 2008)
Volume 13, Issue 3, Pages (March 2012)
Volume 15, Issue 8, Pages (July 2014)
Volume 12, Issue 2, Pages (February 2011)
Volume 12, Issue 9, Pages (September 2013)
Volume 15, Issue 4, Pages (April 2014)
Volume 373, Issue 9663, Pages (February 2009)
Volume 15, Issue 4, Pages (April 2014)
Volume 9, Issue 10, Pages (October 2008)
Volume 14, Issue 8, Pages (July 2013)
Volume 18, Issue 7, Pages (July 2017)
Volume 14, Issue 8, Pages (July 2013)
Volume 5, Issue 11, Pages (November 2018)
Volume 12, Issue 7, Pages (July 2011)
Volume 15, Issue 6, Pages (May 2014)
Volume 18, Issue 3, Pages (March 2017)
Volume 379, Issue 9812, Pages (January 2012)
Lung cancer diagnosis and staging with endobronchial ultrasound-guided transbronchial needle aspiration compared with conventional approaches: an open-label,
Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild- type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2–3 randomised.
Volume 387, Issue 10023, Pages (March 2016)
Volume 14, Issue 6, Pages (May 2013)
Volume 14, Issue 11, Pages (October 2013)
Volume 373, Issue 9666, Pages (March 2009)
Volume 18, Issue 3, Pages (March 2017)
Volume 385, Issue 9962, Pages (January 2015)
Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled,
Volume 19, Issue 4, Pages (April 2018)
Volume 371, Issue 9625, Pages (May 2008)
Volume 16, Issue 15, Pages (November 2015)
Volume 388, Issue 10055, Pages (October 2016)
Volume 15, Issue 6, Pages (May 2014)
Volume 392, Issue 10162, Pages (December 2018)
Volume 14, Issue 6, Pages (May 2013)
Volume 13, Issue 11, Pages (November 2012)
Volume 16, Issue 15, Pages (November 2015)
Volume 5, Issue 4, Pages (April 2018)
Volume 16, Issue 8, Pages (August 2015)
Volume 14, Issue 8, Pages (July 2013)
Volume 19, Issue 10, Pages (October 2018)
Volume 15, Issue 6, Pages (May 2014)
Volume 15, Issue 1, Pages (January 2014)
Volume 15, Issue 8, Pages (July 2014)
Volume 11, Issue 3, Pages (March 2010)
Volume 11, Issue 1, Pages (January 2010)
Volume 18, Issue 10, Pages (October 2017)
Volume 376, Issue 9747, Pages (October 2010)
Volume 14, Issue 9, Pages (August 2013)
Volume 13, Issue 7, Pages (July 2014)
DHA-Paclitaxel (Taxoprexin) as First-Line Treatment in Patients with Stage IIIB or IV Non-small Cell Lung Cancer: Report of a Phase II Open-Label Multicenter.
Volume 372, Issue 9632, Pages (July 2008)
Phase 2 Study of Sorafenib in Malignant Mesothelioma Previously Treated with Platinum-Containing Chemotherapy  Sophie Papa, MRCP, PhD, Sanjay Popat, FRCP,
Volume 14, Issue 7, Pages (June 2013)
Volume 371, Issue 9611, Pages (February 2008)
Volume 20, Issue 7, Pages (July 2019)
Presentation transcript:

Volume 15, Issue 8, Pages 894-904 (July 2014) Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial  Susan J Dutton, MSc, Prof David R Ferry, PhD, Prof Jane M Blazeby, MD, Haider Abbas, MRCP, Asa Dahle-Smith, MBChB, Wasat Mansoor, PhD, Joyce Thompson, FRCP, Mark Harrison, PhD, Anirban Chatterjee, FRCR, Stephen Falk, MD, Angel Garcia-Alonso, MD, David W Fyfe, MD, Richard A Hubner, PhD, Tina Gamble, Lynnda Peachey, BSc, Mina Davoudianfar, BA, Sarah R Pearson, BSc, Patrick Julier, MSc, Prof Janusz Jankowski, PhD, Rachel Kerr, MD, Russell D Petty, MRCP  The Lancet Oncology  Volume 15, Issue 8, Pages 894-904 (July 2014) DOI: 10.1016/S1470-2045(14)70024-5 Copyright © 2014 Elsevier Ltd Terms and Conditions

Figure 1 Trial profile PRO=patient-reported outcome. The Lancet Oncology 2014 15, 894-904DOI: (10.1016/S1470-2045(14)70024-5) Copyright © 2014 Elsevier Ltd Terms and Conditions

Figure 2 Survival Kaplan-Meier plots of overall survival by (A) treatment and (B) performance status, and (C) progression-free survival by treatment. HR=hazard ratio. PS=performance status. The Lancet Oncology 2014 15, 894-904DOI: (10.1016/S1470-2045(14)70024-5) Copyright © 2014 Elsevier Ltd Terms and Conditions

Figure 3 Hazard ratio plot of the treatment effect by prognostic factors for progression-free survival The Lancet Oncology 2014 15, 894-904DOI: (10.1016/S1470-2045(14)70024-5) Copyright © 2014 Elsevier Ltd Terms and Conditions

Figure 4 Waterfall plots for patients with measurable disease at baseline and 4 weeks, response confirmed at 8 weeks Green=recorded as progressed by 8 weeks, might have been new lesions. Grey=not reported as progressed. RECIST=Response Evaluation Criteria in Solid Tumors. The Lancet Oncology 2014 15, 894-904DOI: (10.1016/S1470-2045(14)70024-5) Copyright © 2014 Elsevier Ltd Terms and Conditions

Figure 5 Mean raw scores for prespecified patient-reported outcomes at all timepoints Higher score equates to better quality of life or more symptoms. The Lancet Oncology 2014 15, 894-904DOI: (10.1016/S1470-2045(14)70024-5) Copyright © 2014 Elsevier Ltd Terms and Conditions

Figure 6 Mean change in health-related quality-of-life outcomes from baseline to 4 weeks Positive values on the functioning scale and negative values on the symptom scale denote benefit from gefitinib compared with placebo. The Lancet Oncology 2014 15, 894-904DOI: (10.1016/S1470-2045(14)70024-5) Copyright © 2014 Elsevier Ltd Terms and Conditions